{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:25:05Z","timestamp":1790231105829,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.maturitas.2018.10.012","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T12:06:30Z","timestamp":1540555590000},"page":"67-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"special_numbering":"C","title":["Gout \u2013 An update of aetiology, genetics, co-morbidities and management"],"prefix":"10.1016","volume":"118","author":[{"given":"Philip C.","family":"Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.maturitas.2018.10.012_bib0005","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.maturitas.2014.05.001","article-title":"Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities","volume":"78","author":"Robinson","year":"2014","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2018.10.012_bib0010","doi-asserted-by":"crossref","first-page":"k3951","DOI":"10.1136\/bmj.k3951","article-title":"Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts","volume":"363","author":"Major","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.maturitas.2018.10.012_bib0015","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1172\/JCI103966","article-title":"The renal excretion of uric acid in patients with gout and in nongouty subjects","volume":"38","author":"Nugent","year":"1959","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.maturitas.2018.10.012_bib0020","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/art.10792","article-title":"Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.maturitas.2018.10.012_bib0025","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41584-018-0004-x","article-title":"An update on the genetics of hyperuricaemia and gout","volume":"14","author":"Major","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.maturitas.2018.10.012_bib0030","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/ncomms1756","article-title":"Decreased extra-renal urate excretion is a common cause of hyperuricemia","volume":"3","author":"Ichida","year":"2012","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.maturitas.2018.10.012_bib0035","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/rheumatology\/ker361","article-title":"National prevalence of gout derived from administrative health data in Aotearoa New Zealand","volume":"51","author":"Winnard","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.maturitas.2018.10.012_bib0040","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.semnephrol.2011.08.005","article-title":"Population heterogeneity in the genetic control of serum urate","volume":"31","author":"Merriman","year":"2011","journal-title":"Semin. Nephrol."},{"issue":"4","key":"10.1016\/j.maturitas.2018.10.012_bib0045","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/annrheumdis-2017-212416","article-title":"Mitochondrial genetic variation and gout in Maori and Pacific people living in Aotearoa New Zealand","volume":"77","author":"Gosling","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.maturitas.2018.10.012_bib0050","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1093\/rheumatology\/kex295","article-title":"Functional non-synonymous variants of ABCG2 and gout risk","volume":"56","author":"Stiburkova","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.maturitas.2018.10.012_bib0055","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000464","article-title":"Multiple common and rare variants of ABCG2 cause gout","volume":"3","author":"Higashino","year":"2017","journal-title":"RMD Open"},{"issue":"Suppl","key":"10.1016\/j.maturitas.2018.10.012_bib0060","doi-asserted-by":"crossref","first-page":"A144","DOI":"10.1136\/annrheumdis-2018-eular.4981","article-title":"Identification of new and rare variants in abcg2, slc22a1 and aldh16a1 genes in crystal-proven early-onset gout","volume":"77","author":"Collet","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"1-3","key":"10.1016\/j.maturitas.2018.10.012_bib0065","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cbi.2012.12.018","article-title":"ALDH16A1 is a novel non-catalytic enzyme that may be involved in the etiology of gout via protein-protein interactions with HPRT1","volume":"202","author":"Vasiliou","year":"2013","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.maturitas.2018.10.012_bib0070","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/0002-9343(64)90104-4","article-title":"A familial disorder of uric acid metabolism and central nervous system function","volume":"36","author":"Lesch","year":"1964","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.maturitas.2018.10.012_bib0075","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41588-018-0047-6","article-title":"Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases","volume":"50","author":"Kanai","year":"2018","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.maturitas.2018.10.012_bib0080","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.rdc.2017.04.004","article-title":"Genomic influences on hyperuricemia and gout","volume":"43","author":"Merriman","year":"2017","journal-title":"Rheum. Dis. Clin. North Am."},{"issue":"1","key":"10.1016\/j.maturitas.2018.10.012_bib0085","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/art.23245","article-title":"Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey","volume":"59","author":"Choi","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"9417","key":"10.1016\/j.maturitas.2018.10.012_bib0090","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(04)16000-5","article-title":"Alcohol intake and risk of incident gout in men: a prospective study","volume":"363","author":"Choi","year":"2004","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.maturitas.2018.10.012_bib0095","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa035700","article-title":"Purine-rich foods, dairy and protein intake, and the risk of gout in men","volume":"350","author":"Choi","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.maturitas.2018.10.012_bib0100","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/imj.12661","article-title":"Comprehensive dietary education in treated gout patients does not further improve serum urate","volume":"45","author":"Holland","year":"2015","journal-title":"Intern. Med. J."},{"issue":"6","key":"10.1016\/j.maturitas.2018.10.012_bib0105","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/art.37925","article-title":"Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial","volume":"65","author":"Stamp","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.maturitas.2018.10.012_bib0110","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1445-5994.1973.tb03115.x","article-title":"Alteration of urate metabolism by weight reduction","volume":"3","author":"Emmerson","year":"1973","journal-title":"Aust. N. Z. J. Med."},{"issue":"5","key":"10.1016\/j.maturitas.2018.10.012_bib0115","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/annrheumdis-2013-203970","article-title":"Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study","volume":"73","author":"Dalbeth","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.maturitas.2018.10.012_bib0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039321","article-title":"Serum uric acid and adiposity: deciphering causality using a bidirectional Mendelian randomization approach","volume":"7","author":"Lyngdoh","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.maturitas.2018.10.012_bib0125","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/key229","article-title":"Genetic association between adiposity and gout: a Mendelian randomization study","author":"Larsson","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.maturitas.2018.10.012_bib0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2018.02.009","article-title":"Serum urate as surrogate endpoint for flares in people with gout: a systematic review and meta-regression analysis","author":"Stamp","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.maturitas.2018.10.012_bib0135","doi-asserted-by":"crossref","first-page":"j1794","DOI":"10.1136\/bmj.j1794","article-title":"The Dietary Approaches to Stop Hypertension (DASH) diet, Western diet, and risk of gout in men: prospective cohort study","volume":"357","author":"Rai","year":"2017","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.maturitas.2018.10.012_bib0140","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1136\/annrheumdis-2016-209958","article-title":"Effects of bariatric surgery on gout incidence in the Swedish Obese Subjects study: a non-randomised, prospective, controlled intervention trial","volume":"76","author":"Maglio","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.maturitas.2018.10.012_bib0145","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007\u20132008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.maturitas.2018.10.012_bib0150","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","article-title":"Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study","volume":"82","author":"Campion","year":"1987","journal-title":"Am. J. Med."},{"issue":"7","key":"10.1016\/j.maturitas.2018.10.012_bib0155","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/annrheumdis-2017-212288","article-title":"Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis","volume":"77","author":"Dalbeth","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.maturitas.2018.10.012_bib0160","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1136\/annrheumdis-2014-206397","article-title":"Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study","volume":"74","author":"Dalbeth","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.maturitas.2018.10.012_bib0165","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2013-203545","article-title":"Effect of bariatric surgery on the inflammatory response to monosodium urate crystals: a prospective study","volume":"72","author":"Dalbeth","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.maturitas.2018.10.012_bib0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147939","article-title":"The toll-like receptor 4 (TLR4) variant rs2149356 and risk of gout in european and polynesian sample sets","volume":"11","author":"Rasheed","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.maturitas.2018.10.012_bib0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064845","article-title":"Association of TLR4 Gene rs2149356 polymorphism with primary gouty arthritis in a case-control study","volume":"8","author":"Qing","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.maturitas.2018.10.012_bib0180","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.4049\/jimmunol.0803777","article-title":"A role of IgM antibodies in monosodium urate crystal formation and associated adjuvanticity","volume":"182","author":"Kanevets","year":"2009","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.maturitas.2018.10.012_bib0185","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1517\/14656566.2015.997213","article-title":"Advances in pharmacotherapy for the treatment of gout","volume":"16","author":"Robinson","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"issue":"9","key":"10.1016\/j.maturitas.2018.10.012_bib0190","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1136\/annrheumdis-2014-205304","article-title":"Hyperuricaemia and gout: time for a new staging system?","volume":"73","author":"Dalbeth","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.maturitas.2018.10.012_bib0195","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3899\/jrheum.150310","article-title":"An observational study of gout prevalence and quality of care in a national australian general practice population","volume":"42","author":"Robinson","year":"2015","journal-title":"J. Rheumatol."},{"issue":"11","key":"10.1016\/j.maturitas.2018.10.012_bib0200","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","article-title":"Global epidemiology of gout: prevalence, incidence and risk factors","volume":"11","author":"Kuo","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"issue":"4","key":"10.1016\/j.maturitas.2018.10.012_bib0205","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/ard.32.4.386","article-title":"Effect of stilboestrol on levels of uric acid in plasma and urine","volume":"32","author":"Nicholls","year":"1973","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.maturitas.2018.10.012_bib0210","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jbspin.2013.12.001","article-title":"Arthritis of the first metatarsophalangeal joint is not always gout: a prospective cohort study in primary care patients","volume":"81","author":"Kienhorst","year":"2014","journal-title":"Joint Bone Spine"},{"issue":"4","key":"10.1016\/j.maturitas.2018.10.012_bib0215","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/rheumatology\/keu378","article-title":"The validation of a diagnostic rule for gout without joint fluid analysis: a prospective study","volume":"54","author":"Kienhorst","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"13","key":"10.1016\/j.maturitas.2018.10.012_bib0220","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/archinternmed.2010.196","article-title":"A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis","volume":"170","author":"Janssens","year":"2010","journal-title":"Arch. Intern. Med."},{"issue":"10","key":"10.1016\/j.maturitas.2018.10.012_bib0225","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","article-title":"2015 gout classification criteria: an American College of Rheumatology\/European League against rheumatism collaborative initiative","volume":"74","author":"Neogi","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.maturitas.2018.10.012_bib0230","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/rheumatology\/kes253","article-title":"Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999-2009","volume":"52","author":"Robinson","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.maturitas.2018.10.012_bib0235","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","article-title":"Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008","volume":"125","author":"Zhu","year":"2012","journal-title":"Am. J. Med."},{"issue":"8","key":"10.1016\/j.maturitas.2018.10.012_bib0240","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nrrheum.2016.102","article-title":"Insight into rheumatological cause and effect through the use of Mendelian randomization","volume":"12","author":"Robinson","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"issue":"5","key":"10.1016\/j.maturitas.2018.10.012_bib0245","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/hy1101.092839","article-title":"Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism","volume":"38","author":"Mazzali","year":"2001","journal-title":"Hypertension"},{"issue":"9732","key":"10.1016\/j.maturitas.2018.10.012_bib0250","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(10)60391-1","article-title":"Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial","volume":"375","author":"Noman","year":"2010","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.maturitas.2018.10.012_bib0255","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jama.300.8.924","article-title":"Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial","volume":"300","author":"Feig","year":"2008","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.maturitas.2018.10.012_bib0260","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1161\/HYPERTENSIONAHA.112.196980","article-title":"Uric acid reduction rectifies prehypertension in obese adolescents","volume":"60","author":"Soletsky","year":"2012","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.maturitas.2018.10.012_bib0265","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/VHRM.S4265","article-title":"Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress","volume":"5","author":"George","year":"2009","journal-title":"Vasc. Health Risk Manag."},{"issue":"7","key":"10.1016\/j.maturitas.2018.10.012_bib0270","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/annrheumdis-2014-205269","article-title":"Allopurinol initiation and all-cause mortality in the general population","volume":"74","author":"Dubreuil","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.maturitas.2018.10.012_bib0275","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.maturitas.2018.10.012_bib0280","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am. J. Med."},{"issue":"1","key":"10.1016\/j.maturitas.2018.10.012_bib0285","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/annrheumdis-2013-203779","article-title":"Revisiting comorbidities in gout: a cluster analysis","volume":"74","author":"Richette","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.maturitas.2018.10.012_bib0290","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/rheumatology\/key096","article-title":"Comorbidity clusters in people with gout: an observational cohort study with linked medical record review","volume":"57","author":"Bevis","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.maturitas.2018.10.012_bib0295","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"6","key":"10.1016\/j.maturitas.2018.10.012_bib0300","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/annrheumdis-2012-201676","article-title":"Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study","volume":"72","author":"Rees","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.maturitas.2018.10.012_bib0305","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial","volume":"392","author":"Doherty","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.maturitas.2018.10.012_bib0310","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s10067-013-2168-8","article-title":"A qualitative and quantitative analysis of the characteristics of gout patient education resources","volume":"32","author":"Robinson","year":"2013","journal-title":"Clin. Rheumatol."},{"issue":"3","key":"10.1016\/j.maturitas.2018.10.012_bib0315","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.maturitas.2018.10.012_bib0320","doi-asserted-by":"crossref","DOI":"10.1002\/art.40583","article-title":"Implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial and associated FDA public safety alert","author":"Choi","year":"2018","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"10.1016\/j.maturitas.2018.10.012_bib0325","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.amjmed.2012.05.025","article-title":"Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial","volume":"125","author":"Taylor","year":"2012","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.maturitas.2018.10.012_bib0330","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/RHU.0000000000000235","article-title":"Does starting allopurinol prolong acute treated gout? A randomized clinical trial","volume":"21","author":"Hill","year":"2015","journal-title":"J. Clin. Rheumatol."},{"issue":"6","key":"10.1016\/j.maturitas.2018.10.012_bib0335","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jbspin.2015.02.021","article-title":"Significance of the initiation time of urate-lowering therapy in gout patients: a retrospective research","volume":"82","author":"Feng","year":"2015","journal-title":"Joint Bone Spine"},{"issue":"1","key":"10.1016\/j.maturitas.2018.10.012_bib0340","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.maturitas.2018.10.012_bib0345","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex156","article-title":"The british society for rheumatology guideline for the management of gout","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatology Oxford (Oxford)"},{"issue":"4","key":"10.1016\/j.maturitas.2018.10.012_bib0350","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.maturitas.2018.10.012_bib0355","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s13075-017-1491-x","article-title":"The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial","volume":"19","author":"Stamp","year":"2017","journal-title":"Arthritis Res. Ther."},{"issue":"12","key":"10.1016\/j.maturitas.2018.10.012_bib0360","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1136\/annrheumdis-2017-211873","article-title":"Allopurinol dose escalation to achieve serum urate below 6 mg\/dL: an open-label extension study","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.maturitas.2018.10.012_bib0365","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","article-title":"A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.maturitas.2018.10.012_bib0370","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5415\/apallergy.2016.6.2.77","article-title":"T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevance","volume":"6","author":"Yun","year":"2016","journal-title":"Asia Pac. Allergy"},{"key":"10.1016\/j.maturitas.2018.10.012_bib0375","first-page":"1","article-title":"Febuxostat for the treatment of hyperuricaemia in gout","author":"Robinson","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"issue":"11","key":"10.1016\/j.maturitas.2018.10.012_bib0380","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.maturitas.2018.10.012_bib0385","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jjcc.2016.02.015","article-title":"Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia","volume":"69","author":"Kojima","year":"2017","journal-title":"J. Cardiol."},{"issue":"7","key":"10.1016\/j.maturitas.2018.10.012_bib0390","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005354","article-title":"Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia","volume":"4","author":"MacDonald","year":"2014","journal-title":"BMJ Open"},{"issue":"13","key":"10.1016\/j.maturitas.2018.10.012_bib0395","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout","volume":"378","author":"White","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.maturitas.2018.10.012_bib0400","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/art.11376","article-title":"New standards for uric acid excretion and evidence for an inducible transporter","volume":"49","author":"Simkin","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.maturitas.2018.10.012_bib0405","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/ar3191","article-title":"A proposal for identifying the low renal uric acid clearance phenotype","volume":"12","author":"Indraratna","year":"2010","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/j.maturitas.2018.10.012_bib0410","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3899\/jrheum.121301","article-title":"Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population","volume":"40","author":"Pui","year":"2013","journal-title":"J. Rheumatol."},{"issue":"17","key":"10.1016\/j.maturitas.2018.10.012_bib0415","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1080\/14656566.2017.1401609","article-title":"Lesinurad for the treatment of hyperuricaemia in people with gout","volume":"18","author":"Robinson","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"issue":"10","key":"10.1016\/j.maturitas.2018.10.012_bib0420","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"2","key":"10.1016\/j.maturitas.2018.10.012_bib0425","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.maturitas.2018.10.012_bib0430","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3899\/jrheum.170199","article-title":"The cost-effectiveness of biannual serum urate (SU) monitoring after reaching target in gout: a health economic analysis comparing SU monitoring","volume":"45","author":"Robinson","year":"2018","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.maturitas.2018.10.012_bib0435","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12916-017-0878-5","article-title":"The genetics of gout: towards personalised medicine?","volume":"15","author":"Dalbeth","year":"2017","journal-title":"BMC Med."},{"issue":"2","key":"10.1016\/j.maturitas.2018.10.012_bib0440","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/BOR.0000000000000367","article-title":"Major unanswered questions in the clinical gout field","volume":"29","author":"Stamp","year":"2017","journal-title":"Curr. Opin. Rheumatol."},{"issue":"1","key":"10.1016\/j.maturitas.2018.10.012_bib0445","first-page":"22","article-title":"Review: gout: a roadmap to approaches for improving global outcomes","volume":"69","author":"Dalbeth","year":"2017","journal-title":"."}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512218305371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512218305371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:13:14Z","timestamp":1759914794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512218305371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":89,"alternative-id":["S0378512218305371"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2018.10.012","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gout \u2013 An update of aetiology, genetics, co-morbidities and management","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2018.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}